Investigational drug therapies currently in early-stage clinical development for the treatment of clostridioides (clostridium) difficile infection.
Expert opinion on investigational drugs
ACX-362F; CRS3123; DS-2969b; LFF571; MCB3681/MCB3837; RBX 2660; ribaxamase; ridinilazole
INTRODUCTION: Clostridioides (Clostridium) difficile Infection (CDI) is an urgent global threat causing ~500,000 infections annually in the United States of America (USA) and is associated with a 36% 30-day attributable mortality rate. Despite the availability of three therapeutic agents, CDI recurrence occurs in 20-40% of patients, with a 30-40% second recurrence rate in these patients. Consequently, there is a need for novel agents for treating CDI. Areas covered: We searched MEDLINE, PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov for agents in early stages of clinical development. These drugs include ACX-362E, DS-2969b, LFF 571, RBX2660, ribaxamase, ridinilazole that have advanced to at least phase 2 and several other drugs in phase 1 development. Expert opinion: The challenge for these new agents is three-fold: (1) to have a novel approach such as a different target/mechanism of action; (2) be 'significantly' better than existing agents in regard to 'sustained clinical response'; or (3) be priced at a reasonable cost when it comes to market or perhaps all three. Their utility can only be proven by clinical trials.
Tran, Mai-Chi N; Kullar, Ravina; and Goldstein, Ellie J C, "Investigational drug therapies currently in early-stage clinical development for the treatment of clostridioides (clostridium) difficile infection." (2019). Articles, Abstracts, and Reports. 1155.